Commentary on the next two abstracts follows the second abstract. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD - J Urol 2003;169:1143-1149

Author： Trump D.L.  

Publisher： Elsevier

ISSN： 1078-1439

Source： Urologic Oncology: Seminars and Original Investigations, Vol.21, Iss.5, 2003-09, pp. : 410-410

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD - J Clin Oncol 2003;21:679-689

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 410-411

Elsevier

Access to resources Recommend Favorite

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 - Prostate 2003;54(4):249-257

By Bosland M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 414-415

Elsevier

Access to resources Recommend Favorite

The evolving role of docetaxel in the management of androgen independent prostate cancer - Khan MA, Carducci MA, Partin AW, Urological Institute, Johns Hopkins Hospital, Baltimore, MD. Journal of Urology 2003;170:1709-1716

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 489-490

Elsevier

Access to resources Recommend Favorite

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA - J Clin Oncol 2002;20:2017-2024

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 412-413

Elsevier

Access to resources Recommend Favorite

Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer - Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA, Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI. J Natl Cancer Inst 2003;95:661-668

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 488-488

Elsevier

Access to resources Recommend Favorite